Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021

  • Published: Aug 2017
  • Pages: 78
  • SKU: IRTNTR14217

Enjoy complimentary customisation on priority with our Enterprise License!

Get me the latest version! (includes COVID-19 impact)
Safe and Secure SSL Encrypted

  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

This industry research report identifies Bristol-Myers Squibb, Novartis, Pfizer, and F. Hoffmann-La Roche as the key vendors in the global graft vs host disease (GVHD) treatment market. This industry research report also presents a competitive analysis of the market by disease type (acute GVCD and chronic GVCD) and by geography (the Americas, APAC, and EMEA). 

Overview of the global graft vs host disease (GVHD) treatment market

Research analysis of the global GVHD treatment market identifies the growing number of organ transplantation cases as one of the major factors that will have a positive impact on the growth of the market. The rise in chronic diseases across the globe has led to the growth in the need for organ transplantation. It has been observed that in 2015, the US witnessed more than 30,000 organ transplants cases, which has increased about 5% when compared to the previous year. Similarly, countries such as Australia also witnesses increasing cases of organ transplantation. This rising number of organ transplants will subsequently augment the growth prospects of the GVHD treatment market. According to the graft versus host disease GVHD treatment industry analysis, this market will grow at a CAGR of more than 7% by 2021.

The increasing applications of bone marrow transplant are one of the major graft versus host disease market trends which will gain traction in the market growth during the next four years. Bone marrow that was widely used only in the treatment of cancer has found significance in the treatment of various cardiovascular, autoimmune, neurological, and Myelodysplastic diseases. According to the University of Washington School of Medicine in the US, clinical trials carried out by injecting bone marrow cells directly into the heart of individuals with ischemic cardiomyopathy resulted in considerable improvements. Such trials will increase the number of bone marrow transplantations in the coming years, which will subsequently drive the growth of the GVHD market.

Competitive landscape and key vendors

The market has the presence of several large and small vendors and appears to be highly fragmented and competitive. The vendors in the market are forming pricing strategies to sustain the increasing competition. Additionally, the vendors are investing heavily in R&D to launch effective drugs and are also forming strategic alliances to strengthen their market presence. For instance, Bristol-Myers Squibb recently formed a strategic alliance with Nordic Bioscience for technological advancement.

The leading vendors in the market are 

  • Bristol-Myers Squibb
  • Novartis
  • Pfizer
  • F. Hoffmann-La Roche

The other prominent vendors in the market are Abbott, AbbVie, Allergan, Anterogen, Astellas Pharma, Athersys, Baxter, Caladrius, Cellular Biomedicine Group, Cipla, Eisai, Eli Lilly, GlaxoSmithKline, Glenmark, Helsinn Healthcare, Heron Therapeutics, Incyte Corporation, IPCA Laboratories, Kadmon Holdings, Lupin, Osiris Therapeutics, RedHill, Sanofi, Shire, Sun Pharmaceutical Industries, Takeda Pharmaceutical, and ViaCyte.

Segmentation by disease type and analysis of the GVHD treatment market

  • Acute GVCD
  • Chronic GVCD

During 2016, the acute GVCD segment accounted for the major shares for this market. This is mainly due to the increasing prevalence of various diseases including cancer that led to the growth in the number of organ transplantations. Owing to factors such as the rise in awareness, better diagnosis, and early approach to treatment, the prevalence of acute GVHD is high in the developed countries.

Geographical segmentation and analysis of the GVHD treatment market

  • Americas
  • APAC
  • EMEA

This market study estimates that in terms of geographic regions, the Americas will be the major revenue contributor to the GVHD treatment market by 2021. The increasing number of transplantation procedures and the growing healthcare infrastructure will fuel the growth prospects of the market in this region. Moreover, the increasing cases of organ failures due to the unhealthy lifestyle and dietary habits of the people and the approvals of new drugs for the treatment of GVHD, will also drive the market’s growth in this region.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2021?
  • What are the key factors driving the global graft vs host disease (GVHD) treatment market?
  • What are the key market trends impacting the growth of the global graft vs host disease (GVHD) treatment market?
  • What are the challenges to market growth?
  • Who are the key vendors in the global graft vs host disease (GVHD) treatment market?
  • What are the market opportunities and threats faced by the vendors in the global graft vs host disease (GVHD) treatment market?
  • Trending factors influencing the market shares of the Americas, APAC, and EMEA.
  • What are the key outcomes of the five forces analysis of the global graft vs host disease (GVHD) treatment market?

Technavio also offers customization on reports based on specific client requirement.


PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Disease overview

PART 06: Market overview

  • Five forces analysis

PART 07: Pipeline landscape

PART 08: Market segmentation by disease type

  • Acute GVHD

PART 09: Geographical segmentation

  • GVHD treatment market in Americas
  • GVHD treatment market in EMEA
  • GVHD treatment market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges

  • Market drivers
  • Market challenges

PART 12: Market trends

  • Inorganic growth strategies
  • Newer applications of bone marrow transplant
  • Growing focus toward the use of biologics

PART 13: Vendor landscape

  • Competitive scenario

PART 14: Key vendor analysis

  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer
  • Other prominent vendors

PART 15: Appendix

  • List of abbreviations

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.


Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases


Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts



  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis


  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape
Interested in this report?
Get your sample now!
  • What are the key global market and the regional market share?
  • What are the revenue-generating key market segments?
  • What are the key factors driving and challenging this market’s growth?
  • Who are the key market vendors and their growth strategies?
  • What are the latest trends influencing the growth of this market?
  • What are the variables influencing the market growth in the primary regions?
  • What are the factors influencing the growth of the parent market?
  • Off-the-shelf research reports
  • Reports can be tailored to meet the customer's needs
  • Trusted by more than 100 fortune 500 organizations
  • Information about the market's key drivers, trends, and challenges
  • Parent market analysis
  • Every week, 50,000 people visit our subscription platform
  • Detailed vendors report with competitive landscape
  • Covid-19 impact and recovery analysis
  • Data on revenue-generating market segments
  • Details on the market shares of various regions
  • Five-force market analysis

Certified ISO 9001 : 2015

We are ISO recognized

We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

We are GDPR and CCPA compliant

We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

Safe and Secure SSL Encrypted

  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

Technavio Get the report (PDF) sent to your email within minutes.

Subscribe & Save

Get lifetime access to our
Technavio Insights

Customized Report as per your Business Needs

  • Our analysts will work directly with you and understand your needs
  • Get data on specified regions or segments, competitor and Vendors
  • Data will be formatted and presented as per your requirements
  • We offer $1000 worth of FREE customization at the time of purchase

Let us help you make report more suited to your requirements.

  • Get a competitive breakdown as per your niche industry
  • Customize the data with various metrics that meet your business prerequisite
  • Understand Revenue Sources, Customers and many more
  • Details on Market Share
  • These customizations are done in a short amount of time by our analysts and industry experts
Enquire Before Buying
17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>